Vertex Data Sharpen Focus On Kidney And Pain Revenue Mix [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 RAINIER data for povetacicept in IgA nephropathy, meeting primary and secondary endpoints with strong efficacy and safety. The company is preparing a Biologics License Application for povetacicept, seeking accelerated FDA review using a priority review voucher. New Phase 4 results for JOURNAVX, suzetrigine, showed support for opioid free recovery across a range of surgical procedures. Vertex is advancing povetacicept into additional kidney indications while building out its pain franchise with JOURNAVX. For you as an investor, this latest news adds fresh detail to the broader story at Vertex, which is best known for its cystic fibrosis franchise. The company is now putting more weight behind kidney disease and pain management, two areas with large patient need and established reimbursement frameworks. These clinical and regulatory steps may influence how investors think about the mix of potential future revenu
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- My Top 3 Drug Stocks for March 2026 [Yahoo! Finance]Yahoo! Finance
- Assessing Vertex Pharmaceuticals (VRTX) Valuation After Positive RAINIER Trial Update And Accelerated IgAN Filing [Yahoo! Finance]Yahoo! Finance
- Block upgraded, Starbucks downgraded: Wall Street's top analyst calls [Yahoo! Finance]Yahoo! Finance
- Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals (VRTX) was upgraded by Maxim Group from "hold" to "buy". They now have a $575.00 price target on the stock.MarketBeat
VRTX
Earnings
- 2/12/26 - Beat
VRTX
Sec Filings
- 3/17/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 144
- VRTX's page on the SEC website